Introduction
============

Type 1 diabetes is believed to result from a complex interplay between genetic predisposition, the immune system, and environmental factors.[@ref1] In recent decades there has been a rapid rise in the incidence of childhood type 1 diabetes worldwide, especially in those under the age of 5.[@ref2] [@ref3] [@ref4] [@ref5] [@ref6] In Europe, from 1989-2003 the average annual increase was 3.9%, too fast to be accounted for by genetics alone.[@ref4] Evidence in support of a putative role for viral infections in the development of type 1 diabetes comes from epidemiological studies that have shown a significant geographical variation in incidence, a seasonal pattern to disease presentation,[@ref2] [@ref3] [@ref7] [@ref8] and an increased incidence of diabetes after enterovirus epidemics.[@ref9]

Enteroviruses are perhaps the most well studied environmental factor in relation to type 1 diabetes. A possible link was first reported by Gamble et al in 1969,[@ref10] with many subsequent studies, in humans and animal models of diabetes, showing an association, particularly with coxsackievirus B-4. Higher rates of enterovirus infection, defined by detection of enterovirus IgM or IgG, or both, viral RNA with reverse transcription polymerase chain reaction (RT PCR), and viral capsid protein, have been found in patients with diabetes at diagnosis compared with controls.[@ref11] [@ref12] [@ref13] [@ref14] [@ref15] [@ref16] [@ref17] Prospective studies have also shown more enterovirus infections in children who developed islet autoantibodies or subsequent diabetes, or both; as well as a temporal relation between infection and autoimmunity.[@ref13] [@ref18] [@ref19] [@ref20]

The relation between enterovirus infection and diabetes is not consistent across all studies,[@ref21] [@ref22] [@ref23] [@ref24] however, and the subject remains controversial.[@ref25] Furthermore, in animal models viral infections might also protect from diabetes.[@ref25] A systematic review of coxsackie B virus serological studies did not show an association with type 1 diabetes,[@ref26] but to date there has been no systematic review of molecular studies. Based on the hypothesis that enterovirus infection increases the risk of pancreatic islet autoimmunity or type 1 diabetes, or both, we carried out a systematic review of controlled studies that used molecular virological methods to investigate the association between enteroviruses and type 1 diabetes.

Methods
=======

Two reviewers (WGY and MEC) independently conducted a systematic search for controlled observational studies of enterovirus and type 1 diabetes mellitus. Databases searched were PubMed (from 1965 to May 2010) and Embase (from 1974 to May 2010). Search terms (exploded, all subheadings) used were: 'diabetes mellitus', 'enterovirus', 'coxsackievirus', 'ECHOvirus', 'polymerase chain reaction', 'PCR', 'RNA', 'DNA', 'nucleic acid', and 'capsid protein'. The search was limited to studies in humans in any language and was supplemented by hand searching reference lists in the identified papers and by direct contact with authors.

Studies were eligible for inclusion if they were case-control or cohort studies (including those published as letters or abstracts); measured enterovirus RNA or viral capsid protein in blood, stool, or tissue of patients with pre-diabetes and diabetes; and provided adequate data to enable calculation of odds ratios and 95% confidence intervals. No restrictions were placed on the study population. We included only those studies that used molecular methods for viral detection (such as RT-PCR (reverse transcription-polymerase chain reaction), in situ hybridisation, or immunostaining for detection of viral capsid protein) to identify current or recent infection and because molecular testing is now standard for diagnosis of acute enterovirus infection.

The results of identified studies were classified into two groups, pre-diabetes and diabetes, depending on whether autoimmunity or type 1 diabetes was the outcome. There were four main categories of cases: autoantibody positive, newly diagnosed type 1 diabetes, established type 1 diabetes, and eventual type 1 diabetes. The latter three were combined into the diabetes group.

We calculated unadjusted odds ratios with 95% confidence intervals and P values for enterovirus identification in patients with pre-diabetes versus no diabetes and patients with diabetes versus no diabetes from the published figures using the Mantel-Haenszel method. The analysis was performed with both fixed and random effects models. Because of the presence of significant heterogeneity we have presented only the results from random effects models. Combined odds ratios were also calculated for different subgroups of studies according to study design. Statistical heterogeneity was explored with Cochrane's Q test and the I^2^ statistic, which provides the relative amount of variance of the summary effect caused by heterogeneity between studies.

We assessed study quality using the Newcastle-Ottawa quality assessment scale (NOS) for case-control studies, as recommended by Cochrane collaboration.[@ref27] Three areas were evaluated---selection, comparability, and exposure---giving a possible total score 9, with 5 or more classed as good methods. In the comparability category, studies were assessed as to whether they controlled for age and sampling time as these are the two factors most likely to affect the incidence of enterovirus infection.

Results
=======

Our search returned a total of 114 publications and abstracts. After review of titles and abstracts, we identified and included 25 relevant papers---two letters and 23 articles. We also included data from two studies published as abstracts only. All were case-control studies (six were nested case-control studies that used samples collected prospectively[@ref20] [@ref22] [@ref28] [@ref29] [@ref30]). One was excluded because it was a pilot study[@ref13] analysing the same data as a duplicate publication.[@ref20] Of the 26 remaining studies, eight contained more than one case group[@ref14] [@ref16] [@ref22] [@ref31] [@ref32] [@ref33] [@ref34] [@ref35] and these were analysed separately, giving a total of 34 studies. Of these, nine were studies of pre-diabetes (198 cases and 733 controls) and 25 were studies of diabetes (1733 cases and 1784 controls).

Characteristics of included studies
-----------------------------------

Thirty studies used RT-PCR or in situ hybridisation to detect enterovirus RNA, while four performed immunostaining for the enterovirus capsid protein vp1 on autopsy pancreas specimens (tables 1[](#tbl1){ref-type="table"} and 2[](#tbl2){ref-type="table"}). Within the pre-diabetes group, all except two of the studies defined autoimmunity as positivity for at least one autoantibody associated with type 1 diabetes (table 1[](#tbl1){ref-type="table"}). Study populations varied in age distribution. While most studies investigated children and adolescents (aged 16 and below), some included adults up to age 53.

###### 

 Summary of molecular studies investigating pre-diabetes and enteroviruses

  Study                  Country                                                     Cases/controls   Cases                                                                                              Autoantibodies detected                   Age in cases                                                                    Controls                                                                                                     Method of detection                                 EV type sequenced
  ---------------------- ----------------------------------------------------------- ---------------- -------------------------------------------------------------------------------------------------- ----------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ --------------------------------------------------- --------------------------------------------------------------------
  Al-Shaheeb, 2010^30^   Australia                                                   13/198           Autoantibody positive children with first degree relative with T1DM                                At least two of ICA, GADA, IA2A, or IAA   Birth cohort from VIGR study                                                    Children from same cohort negative for autoantibody                                                          EV RNA in serum (RT-PCR)                            ---
  Coutant, 2002^32^      France                                                      5/49             Autoantibody positive siblings of probands with diabetes                                           ICA, GADA                                 Age 2.4-16.5                                                                    Healthy children matched for age, sex, place, and sampling date                                              EV RNA in serum (RT-PCR)                            ---
  Graves, 2003^22^       USA                                                         13/13            Autoantibody positive (eventual); sibling offspring cohort                                         At least one of IAA, GADA, or ICA         From DAISY cohort study, children at moderate to high risk of developing T1DM   Age matched children from same cohort negative for autoantibody                                              EV RNA in serum, saliva, and rectal swab (RT-PCR)   ---
  13/26                  Autoantibody positive (eventual); newborn screened cohort                                                                                                                                                                                                                                                                                                                                                                                                                  
  Moya-Suri, 2005^33^    Germany                                                     50/50            Autoantibody positive                                                                              At least one of IAA, GADA, ICA, or IA2A   Median age 12, IQR 10-14                                                        Children from same cohort negative for autoantibody                                                          EV RNA in serum (RT-PCR)                            CVB-4, CVB-2, CVB-6
  Salminen, 2003^20^     Finland                                                     41/196           Autoantibody positive children (samples taken 6 months before seroconversion)                      At least one of ICA, GADA, IAA, or IA2A   Birth cohort from DIPP study                                                    Children from same cohort negative for autoantibody                                                          EV RNA in serum (RT-PCR)                            ---
  Sadeharju, 2003^28^    Finland                                                     19/84            Autoantibody positive (eventual), from Trial to Reduce IDDM in Genetically at Risk (TRIGR) study   At least one of IAA, GADA, or IA2A        Birth cohort from TRIGR study                                                   Children from same study cohort negative for autoantibody and matched for sex, HLA, and intervention group   EV RNA in serum (RT-PCR)                            ---
  Salminen, 2004^29^     Finland                                                     12/53            Autoantibody positive (eventual)                                                                   At least one                              Birth cohort from DIPP study                                                    Children from same study cohort negative for autoantibody (matched for age, sex, and HLA DQ haplotype)       EV RNA in stool samples (RT-PCR) and/or serum       PV-3, CVA-9, CVB-3, CVB-4, CVB-5, EV-3, EV-11, EV-18, EV-24, EV-25
  Sarmiento, 2007^16^    Cuba                                                        32/63            First degree relatives with ICA positive T1DM                                                      ICA                                       Mean age 13.5 (SD 9.5), range 1-46                                              Healthy people verified negative for ICA with no family history of diabetes                                  EV RNA in serum (RT-PCR)                            ---

T1DM=type 1 diabetes mellitus; ICA=islet cell autoantibody; GADA=glutamic acid decarboxylase autoantibody; IA2A=islet cell antigen antibody; IAA=insulin autoantibody; EV RNA=enterovirus RNA; RT PCA=reverse transcription-polymerase chain reaction; IQR=interquartile range.

###### 

 Summary of molecular studies investigating type 1 diabetes (T1DM) and enteroviruses

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                Country                      Cases/controls          Cases and details of diabetes                                               Age of cases (years unless specified)   Controls                                                                     Method of detection                                                           EV type sequenced
  ---------------------------------------------------- ---------------------------- ----------------------- --------------------------------------------------------------------------- --------------------------------------- ---------------------------------------------------------------------------- ----------------------------------------------------------------------------- ----------------------------
  Andreoletti, 1997^14^                                France                       12/15                   Newly diagnosed with metabolic decompensation                               Mean 28.2 (SD 10.4)                     Healthy adults                                                               EV RNA in peripheral blood (RT PCR)                                           CVB-3, CVB-4

  Previously diagnosed with metabolic decompensation   Mean 32.6 (SD 13.3)                                                                                                                                                                                                                                                                                                                 

  Buesa-Gomez, 1994^60^                                USA                          2/5                     Fatal acute onset                                                           14 months and 3 years                   Children who died from non-diabetic causes                                   Coxsackie RNA in autopsy pancreatic samples (RT PCR)                          ---

  Clements, 1995^41^                                   UK                           14/45                   Newly diagnosed                                                             Mean 3.9, range 1.4-6.0                 Normal subjects matched for age, sex, sample date, and place                 EV RNA in serum (RT PCR)                                                      CVB-3, CVB-4

  Coutant, 2002^32^                                    France                       16/49                   Newly diagnosed (within 1 month of diagnosis)                               Range \<6                               Healthy children matched for age, sex, sample date, and place                EV RNA in serum (RT PCR)                                                      ---

  Craig, 2003^58^                                      Australia                    206/160                 Newly diagnosed (within 2 weeks of diagnosis)                               Median 8.2, range 0.7-15.7              Children without diabetes from community                                     EV RNA in plasma or stool samples (RT PCR)                                    EV-71

  Dahlquist, 2004^36^                                  Sweden                       600/600                 Eventual diabetes, on Swedish childhood diabetes register                   Neonate                                 People without diabetes from same biobank                                    EV RNA in newborn blood spots (RT PCR)                                        ---

  Dotta, 2007^46^                                      Italy                        6/26                    Recent onset                                                                Range 14-50                             Normal multi-organ donors                                                    EV vp1 immunostaining in autopsy pancreatic samples (Dako anti-vp1)           CVB-4

  Foulis, 1990^38^                                     UK                           147/43                  88 recent onset (duration \<1 year), 59 established (duration 1-19 years)   Range 1-37                              Normal autopsy pancreases from 11 neonates, 21 children, 11 adults           EV vp1 immunostaining in autopsy pancreatic samples                           ---

  Foy, 1995^35^                                        UK                           17/42                   Newly diagnosed (on day of diagnosis)                                       Median 11, range 2-35                   Patients without diabetes, matched for age and sex                           EV RNA in peripheral blood (RT PCR)                                           ---

  38/42                                                Duration 2 months-10 years   Median 11, range 3-16                                                                                                                                                                                                                                                                                  

  Kawashima 2004^61^                                   Japan                        61/58                   Type 1 diabetes                                                             Range 9 months - 40 years               Healthy people                                                               EV RNA in serum (RT PCR)                                                      CVB-2, CVB-3, CVB-4, CVB-5

  Lönnrot, 2000^31^                                    Finland                      11/34                   Eventual diabetes, from DiMe Study                                          Mean 8.4, range 2.6-17                  Children from same study cohort who did not develop T1DM or autoantibodies   EV RNA in serum (RT PCR)                                                      ---

  47/34                                                Newly diagnosed              Mean 4.4                                                                                                                                                                                                                                                                                               

  Maha, 2003^34^                                       Egypt                        40/30                   Recent onset (\<1 year)                                                     Mean 11.30 (SD 2.16)                    Normal healthy children                                                      EV RNA in serum (RT PCR via tissue culture)                                   CVB-4, CVB-6

  30/30                                                Duration \>1 year            Mean 11.80 (SD 2.70)                                                                                                                                                                                                                                                                                   

  Moya-Suri, 2005^33^                                  Germany                      47/50                   Newly diagnosed (median 5 days from diagnosis)                              Median 13, IQR 11-15                    Children from same study negative autoantibodies                             EV RNA in serum (RT PCR)                                                      CVB-4, CVB-2, CVB-6

  Nairn, 1999^12^                                      UK                           110/182                 Newly diagnosed (within 1 week from diagnosis)                              Mean 7.1, range 3 months-16 years       Children without diabetes (matched for age, location, time of sampling)      EV RNA in serum (RT PCR)                                                      PV1-3, CVA-21, CVA-24,\
                                                                                                                                                                                                                                                                                                                                                                                           EV-70

  Oikarinen, 2007^39^                                  Finland                      12/10                   Established (duration 0-51 years, median 13)                                Median 30, range 18-53                  Patients without diabetes from same hospital department                      vp1 immunostaining in small bowel mucosa (Dako anti-vp1)                      ---

  Richardson, 2009^17^                                 UK                           72/119                  Recent onset (8.2 (SD 4.1) months from diagnosis)                           Mean 12.65 (SD 1.1), range 1-42         Normal autopsy pancreases from 11 neonates, 39 children and 69 adults        EV vp1 immunostaining in autopsy pancreatic samples (Dako anti-vp1)           ---

  Sarmiento, 2007^16^                                  Cuba                         34/68                   Newly diagnosed (0.78 (SD 2.4) days from diagnosis)                         Mean 7.3 (SD 4.5), range 1-15           Healthy subjects, verified ICA negative and no family history of diabetes    EV RNA in serum (RT PCR)                                                      ---

  Schulte, 2010^43^                                    Nether-lands                 10/20                   Newly diagnosed (within 1 month of diagnosis)                               Mean 9.7, range 5-14                    Children of same age range in hospital with non-endocrine disorders          EV RNA in peripheral blood mononuclear cells (RT PCR)                         HEV-B

  Toniolo, 2010^44^                                    Italy                        112/58                  Newly diagnosed                                                             Mean 6.8, median 9.0,\                  Healthy children                                                             EV RNA in peripheral blood (RT PCR)                                           HEV-A, HEV-B, HEV-C, HEV-D
                                                                                                                                                                                        range 2-16                                                                                                                                                                                         

  Yin, 2002^40^                                        Sweden                       24/24                   Newly diagnosed (within 1 week from diagnosis)                              Mean 8.4, range 1.6-15.7                Healthy children from nearby counties                                        EV RNA in PBMCs (RT PCR)                                                      CVB-5, EV-5, CVB-4

  Ylipaasto, 2004^42^                                  Finland/ Germany             65/40                   Duration: few weeks to 19 years                                             Range 18-52                             Non-diabetic pancreases (age-sex matched)                                    EV RNA in autopsy pancreatic samples (RNA probes and in situ hybridisation)   ---
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

EV RNA=enterovirus RNA; RT PCA=reverse transcription-polymerase chain reaction.

Quality of evidence
-------------------

The Newcastle-Ottawa scores ranged from 3 to 8, with 24 studies scoring 5 or more (table 3[](#tbl3){ref-type="table"}), indicating reasonably good methodological quality overall, with no studies reporting a non-response rate.

###### 

 Quality of evidence in molecular studies investigating type 1 diabetes (T1DM) and enteroviruses

  Study                   NHMRC level of evidence\*   Newcastle-Ottawa scale score   Diagnostic criteria for autoimmunity and/or type 1 diabetes given?   Cases and controls matched?   Details of viral detection given?                     
  ----------------------- --------------------------- ------------------------------ -------------------------------------------------------------------- ----------------------------- ----------------------------------- ----- ----- ----- ------------------
  Andreoletti, 1997^14^   III-3                       4                              No                                                                   No                            No                                  No    No    No    Yes (referenced)
  Al-Shaheeb, 2010^30^    II                          7                              Yes                                                                  No                            No                                  No    Yes   Yes   Yes
  Buesa-Gomez, 1994^60^   III-3                       4                              No                                                                   No                            No                                  No    No    No    Yes
  Clements, 1995^41^      III-3                       6                              No                                                                   Yes                           Yes                                 No    Yes   Yes   No
  Coutant, 2002^32^       III-3                       6                              No                                                                   Yes                           Yes                                 No    Yes   Yes   Yes
  Craig, 2003^58^         III-3                       6                              Yes (diabetes register)                                              No                            No                                  No    No    Yes   Yes
  Dahlquist, 2004^36^     II                          7                              Yes (diabetes register)                                              Yes                           No                                  No    No    No    Yes (referenced)
  Dotta, 2007^46^         III-3                       5                              No                                                                   No                            No                                  No    No    NA    Yes
  Foulis, 1990^38^        III-3                       3                              No                                                                   No                            No                                  No    No    NA    Yes
  Foy, 1995^35^           III-3                       6                              Yes                                                                  Yes                           Yes                                 No    No    No    Yes
  Graves, 2003^22^        II                          7                              Yes for autoimmunity, no for diabetes                                Yes                           No                                  No    No    No    No
  Kawashima, 2004^61^     III-3                       5                              No                                                                   No                            No                                  No    No    No    Yes
  Lönnrot, 2000^31^       II                          6                              No                                                                   Yes                           Yes                                 Yes   No    Yes   Yes
  Maha, 2003^34^          III-3                       5                              No                                                                   No                            No                                  No    No    No    Yes
  Moya-Suri, 2005^33^     III-3                       7                              Yes for autoimmunity, no for diabetes                                Yes                           Yes                                 No    No    No    Yes
  Nairn, 1999^12^         III-3                       7                              No                                                                   Yes                           No                                  No    Yes   Yes   Yes (referenced)
  Oikarinen, 2007^39^     III-3                       4                              No                                                                   No                            No                                  No    No    NA    Yes
  Richardson, 2009^17^    III-3                       4                              No                                                                   No                            No                                  No    No    NA    Yes
  Sadeharju, 2003^28^     II                          8                              Yes                                                                  Yes                           Yes                                 Yes   No    Yes   Yes (referenced)
  Salminen, 2003^20^      II                          6                              Yes                                                                  Yes                           Yes                                 Yes   No    No    Yes (referenced)
  Salminen, 2004^29^      II                          7                              Yes                                                                  Yes                           Yes                                 Yes   No    Yes   Yes
  Sarmiento, 2007^16^     III-3                       6                              No                                                                   Yes                           Yes                                 No    Yes   Yes   Yes
  Schulte, 2010^43^       III-3                       4                              No                                                                   No                            No                                  No    No    No    Yes
  Toniolo, 2010^44^       III-3                       7                              Yes                                                                  No                            No                                  No    Yes   No    Yes
  Yin, 2002^40^           III-3                       7                              No                                                                   Yes                           Yes                                 No    Yes   No    Yes
  Ylipaasto, 2004^42^     III-3                       5                              No                                                                   Yes                           Yes                                 No    No    No    Yes

NA=not available.

\*II=nested case-control study; III-3=case-control study.^59^

Pre-diabetes
------------

Figure 1 presents the individual and summary odds ratio of the nine pre-diabetes studies [](#fig1){ref-type="fig"}. Odds ratios ranged from 0.1 to 483, with a summary odds ratio of 3.7 (95% confidence interval 2.1 to 6.8; P\<0.001). There was some evidence for heterogeneity across the studies (χ^2^/df=1.34), but this value did not reach significance (P=0.22). When we analysed the results from the six nested case-control studies separately, the summary odds ratio was 3.0 (1.5 to 6.0; P=0.002) (table 4[](#tbl4){ref-type="table"}).

![**Fig 1** Odds ratios for enterovirus positivity in patients with pre-diabetes versus no diabetes](yeuw797951.f1_default){#fig1}

###### 

 Combined odds ratios for pre-diabetes studies stratified by study type

  Type of study                 No of studies   Combined OR (95% CI)   P value   χ^2^/df\*
  ----------------------------- --------------- ---------------------- --------- -----------
  All                           9               3.7 (2.1 to 6.8)       \<0.001   1.34
  Nested case-control studies   6               3.0 (1.5 to 6.0)       0.002     1.57
  Studies in Europe             5               5.2 (2.8 to 9.6)       \<0.001   0.17

\*Cochrane χ^2^ divided by degrees of freedom. Values \>1 indicate heterogeneity.

Three of the nested case-control studies also separately examined the six or 12 month period preceding the first appearance of autoantibodies.[@ref20] [@ref22] The summary odds ratio was 3.6 (1.3 to 9.8; P=0.01). Five studies also sequenced the HLA haplotypes of their participants and two included those with low risk HLA genotypes. For those with high HLA risk haplotypes (five studies, 112 cases, 551 controls), the combined odds ratio was 3.5 (1.7 to 7.1; P\<0.001).[@ref20] [@ref22] [@ref28] [@ref29] [@ref30] Only two studies (21 cases, 158 controls) included participants with low risk HLA genotypes, with conflicting results (0.4, (0.04 to 4.8)[@ref22] and 9.3 (1.9 to 45)[@ref30]), but the combined odds ratio was not significant (2.3, 0.1 to 56; P=0.62).

Type 1 diabetes
---------------

Figure 2 shows the individual and summary odds ratios of the 25 studies of patients with type 1 diabetes [](#fig2){ref-type="fig"}. All studies except one[@ref32] showed an odds ratio over 1 for enterovirus positivity in patients with diabetes. Odds ratios ranged from 0.24 to 129, with a summary odds ratio of 10 (5.5 to 17; P\<0.001). There was significant heterogeneity across the studies (χ^2^/df=3.21; P\<0.001).

![**Fig 2** Odds ratios for enterovirus positivity in patients with and without diabetes](yeuw797951.f2_default){#fig2}

We carried out a subgroup analysis with respect to method of enterovirus detection (RNA or capsid protein) and case selection (newly diagnosed *v* established *v* eventual diabetes; table 5[](#tbl5){ref-type="table"}, fig 2[](#fig2){ref-type="fig"}). The combined odds ratios for newly diagnosed, established, and eventual diabetes were 13 (6 to 25), 11 (4 to 29), and 1.25 (0.2 to 7), respectively. The combined odds ratio of studies that used RNA detection was 8.8 (4.7 to 17; P\<0.001), while for studies that performed immunostaining for enterovirus capsid protein, the odds ratio was 15 (7.5 to 31). There was no significant heterogeneity across studies that measured enteroviral vp1 protein, probably because of the similarity in study design.

###### 

 Summary odds ratios of diabetes studies including sensitivity analyses

                                          No of studies   OR (95% CI)          P value   χ^2^/df\*
  --------------------------------------- --------------- -------------------- --------- -----------
  Diabetes (all studies)                  25              9.8 (5.5 to 17.4)    \<0.001   3.21
  Method of virus detection:                                                             
   RNA                                    21              8.8 (4.7 to 16.7)    \<0.001   3.37
   vp1                                    4               15.4 (7.5 to 31.5)   \<0.001   0.35
  Case definition:                                                                       
   Newly diagnosed                        12              12.7 (6.4 to 25.2)   \<0.001   2.44
   Established (including recent onset)   11              10.8 (4.0 to 29.4)   \<0.001   2.62
   Eventual                               2               1.3 (0.2 to 6.9)     0.79      1.60
  Study location:                                                                        
   Europe only                            19              8.6 (4.3 to 17.3)    \<0.001   3.75
   Non-European countries                 6               13.5 (7.1 to 25.8)   \<0.001   0.34
  Study quality:                                                                         
    NOS score ≥5                          18              9.0 (4.6 to 17.5)    \<0.001   3.77

NOS=Newcastle-Ottawa.

\*Cochrane χ^2^ divided by degrees of freedom. Values \>1 indicate heterogeneity.

We used sensitivity analyses to test the robustness of the results by country and study quality. For the 19 studies conducted in Europe,[@ref12] [@ref14] [@ref17] [@ref31] [@ref32] [@ref33] [@ref35] [@ref36] [@ref37] [@ref38] [@ref39] [@ref40] [@ref41] [@ref42] [@ref43] [@ref44] the combined odds ratio was 8.6 (4.3 to 17; P\<0.001), with significant heterogeneity (χ^2^/df=3.75, P\<0.001). The odds ratio was comparatively higher for the non-European studies (13.5, 7.1 to 26), with low heterogeneity, though there was considerable overlap of the confidence intervals between the two groups. When we excluded the studies with poor methodological quality (Newcastle-Ottawa score \<5), the combined odds ratio was similar (8.9, 4.6 to 17; P\<0.001). Subgroup analysis by HLA genotype was not performed because none of the studies performed HLA genotyping on all cases and controls.

Discussion
==========

This systematic review of 33 prevalence studies, involving 1931 cases and 2517 controls, shows a clinically significant association between enterovirus infection and islet autoimmunity or type 1 diabetes. The association between enterovirus infection, detected with molecular methods, and diabetes was strong, with almost 10 times the odds of enterovirus infection in children at diagnosis of type 1 diabetes compared with controls (9.8, 5.5 to 17.4), while the odds of infection was also higher in children with pre-diabetes than in controls (3.7, 2.1 to 6.8). There was some evidence for geographical differences; in non-European studies the odds ratio was 13.5 (7.1 to 25.8) compared with 8.6 (4.3 to 17.3) in European studies, though there was considerably overlap in the confidence intervals. While the findings from this meta-analysis of observational studies cannot prove that enterovirus infection has a causal role in pathogenesis of diabetes, the results provide additional support to the direct evidence of enterovirus infection in pancreatic tissue of individuals with type 1 diabetes.[@ref45] [@ref46]

Strengths and weaknesses
------------------------

We made every effort to reduce potential bias in this review, through use of pre-defined inclusion criteria, independent searches by two reviewers, no language restriction, and searching of references lists and conference proceedings. We included studies in children and adults, reducing the risk of bias resulting from high rates background infection in children.[@ref47] [@ref48] Studies from throughout the world were included, reducing the risk of geographical bias related to infection rates. Most studies, however, were from European countries, where the incidence of type 1 diabetes is higher. Given the heterogeneity of the study populations, we used random effects models, providing more conservative effect estimates.

Several limitations could have influenced our findings, including factors inherent in a meta-analysis of observational studies. There was significant heterogeneity in study design and methods used. Only 10 studies matched for three or more potential confounding factors (age, genetic risk, geographical location, and sampling time). Most of the included studies used children without diabetes or who were negative for antibodies as controls, but there could have been unmeasured factors influencing their risk of developing diabetes. Other environmental factors might modify the risk of type 1 diabetes, such as cows' milk,[@ref49] vitamin D,[@ref50] and weight gain in infancy,[@ref51] but it is not possible to control for all of these potential confounders in case-control studies. Finally, enterovirus PCR primers had varying sensitivity and specificity, and not all studies reported the validation and limits of detection of their PCR method. Samples were obtained from various sites (serum, stool, throat swabs, etc) and because enteroviruses invade and replicate at mucosal surfaces, detection rates are likely to be higher in samples obtained from the gastrointestinal tract.[@ref52] [@ref53]

The overall methodological quality of the studies of the studies was relatively good, with 26 publications scoring 5 or more of 9 on the Newcastle-Ottawa scale. Eleven studies included fewer than 50 participants, giving rise to the possibility of small study effects. The four largest studies of diabetes (involving more than 1000 cases and controls), however, showed a clear association between enterovirus infection and clinical diabetes.

Strengths and weaknesses in relation to other studies
-----------------------------------------------------

A previous meta-analysis of coxsackie B virus serological studies found no significant association between type 1 diabetes and serology positivity,[@ref26] though summary estimates were not calculated because of significant heterogeneity between studies. Several major differences between the two meta-analyses could explain the discrepant findings. Firstly, most studies included in our review detected most enteroviruses by using PCR primers targeting the highly conserved 5′ untranslated region of the enterovirus genome, whereas serological studies examined only certain serotypes. Secondly, molecular methods for detection of enteroviruses are significantly more sensitive than serology.[@ref54] [@ref55] Thirdly, the detection of enterovirus RNA or vp1 identifies only current or recent infection. The latter is also a limitation of molecular methods, though this would probably cause bias towards under-reporting of infection rates and estimation of a lower than actual effect size. We could not examine whether participants had multiple enterovirus infections or the same persistent infection before the development of autoimmunity or type 1 diabetes.

Autoimmunity was mostly defined as a positive result for at least one autoantibody associated with type 1 diabetes, and the presence of a single antibody does not confer a high lifetime risk of clinical diabetes compared with positive results for multiple antibodies.[@ref56] [@ref57] Prospective studies are also limited by the frequency of sample collection, which might be only six or 12 months apart, and it is noteworthy that the only prospective study reporting an odds ratio under 1 had the longest sampling intervals.[@ref22] A temporal association between seroconversion to autoimmunity and infection could be under-reported because of lack of sampling at the time of infection or seroconversion, or both, in some individuals.

Maternal enterovirus infection might also be a risk factor for autoimmunity and type 1 diabetes. We did not specify maternal infection in our inclusion criteria, though among the "eventual diabetes" group enterovirus RNA was more commonly detected in dried blood spots from newborn infants who subsequently developed type 1 diabetes. Two of the included studies in the pre-diabetes group examined maternal enterovirus infection by using serology and showed little or no association between infection and subsequent development of autoimmunity in their offspring.[@ref20] [@ref28]

There is conflicting evidence as to whether the presence or absence of high risk HLA genotypes modifies the association between enterovirus infection and type 1 diabetes. Several groups have reported higher rates of enterovirus infection in children with low risk HLA genotypes.[@ref16] [@ref58] Unfortunately, we could not do a subgroup analysis by HLA genotype in the diabetes studies because most studies did not do HLA genotyping in control participants. In the pre-diabetes group, the odds ratio of enterovirus infection in high risk HLA participants (3.5) was not different from the overall odds ratio (3.4), and the conflicting results from the two studies with low risk participants do not support an association between enterovirus infection and autoimmunity. Ideally, future studies should include individuals with low risk HLA genotypes to explore whether genetic risk modifies the effect of enterovirus infection on the risk of type 1 diabetes.

Conclusion
----------

Our results show an association between type 1 diabetes and enterovirus infection, with a more than nine times the risk of infection in cases of diabetes and three times the risk in children with autoimmunity. The odds of having an enterovirus infection in people with established diabetes (odds ratio 11) suggest that persistent enterovirus infection is also common among patients with type 1 diabetes. While it is not possible to determine a causal relation between infection and type 1 diabetes with a randomised controlled trial, larger multicentre international prospective studies could examine interactions between type 1 diabetes and various environmental, geographical, and genetic factors.

### What is already known on this topic

1.  Observational studies have shown an association between enteroviruses and type 1 diabetes

2.  A systematic review of serological studies only found no association

### What this study adds

1.  A review of molecular studies showed an association between current enterovirus infection and type 1 diabetes
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